Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099297 | 0.85 | HSD11B1 (0.60) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3082536 | 0.82 | HSD11B1 (0.56) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3093780 | 0.81 | FPR2 (0.47) | HSD11B1CHRM1ALDH1A1 | |
| SCHEMBL3098913 | 0.80 | OPRM1 (0.59) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3110797 | 0.80 | HSD11B1 (0.70) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3113174 | 0.80 | CHRM1 (0.61) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL5774178 | 0.80 | HSD11B1 (0.67) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3086396 | 0.80 | HSD11B1 (0.67) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3093814 | 0.79 | AVPR1A (0.80) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3082529 | 0.79 | FPR2 (0.46) | HSD11B1CHRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803815-B2 | Indol-3-yl-corbonyl-piperidin-benzoimidazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | claimed |
| EP-1912976-B1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOLE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | EP | claimed |
| EP-1912976-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-23 | — | — | EP | claimed |
| WO-2007009906-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | claimed |
| US-20070021463-A1 | Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives | HOFFMANN-LA ROCHE INC. | 2007-01-25 | — | — | US | claimed |
| US-20100256140-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES | BISSANTZ CATERINA | 2010-10-07 | — | — | US | disclosed |
| US-7803815-B2 | Indol-3-yl-corbonyl-piperidin-benzoimidazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1912976-B1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOLE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1912976-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007009906-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021463-A1 | Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives | HOFFMANN-LA ROCHE INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256140-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES | AVPR1A, AVPR2, AVPR1B | HSD11B1 2549/4885CHRM1 492/4885CHRM2 1474/4885 |
| US-20070021463-A1 | Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives | AVPR1A, AVPR2, AVPR1B | HSD11B1 2549/4885CHRM1 492/4885CHRM2 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.